Please assess the completion status of the following clinical trial:

Trial Title: Postoperative Tramadol/Gabapentin/Ibuprofen Versus Tramadol/Placebo/Ibuprofen

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Child must be scheduled to undergo tonsillectomy (with or without adenoidectomy)~* Child must be between the ages of 4 and 15 at the time of enrollment.~* Child and caregiver must be English-speaking~* The same caregiver (e.g., mother) must agree to complete all study assessments with child to ensure consistency~Exclusion Criteria:~* Child cannot self-assess pain due to conditions such as developmental delays, chromosomal abnormalities, or other syndromes~* Child had significant adverse effects to tramadol, gabapentin and/or ibuprofen in the past~* Child has a known underlying seizure disorder (not febrile seizure)~* Child has known underlying renal or liver dysfunction (with creatinine, aspartate aminotransferase /alanine aminotransferase, more than twice above normal value for age, respectively)~* Child is taking an selective serotonin reuptake inhibitor (SSRI), norepinephrine reuptake inhibitor (SNRI), monoamine oxidase inhibitor (MAOI) or tricyclic

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 15 Years
- Healthy Volunteers: f

Study Arms:
- Tramadol/gabapentin/ibuprofen (Type: ACTIVE_COMPARATOR): (A) Scheduled tramadol 1mg/kg Q6h \[max. 50mg\] for 5 days; plus tramadol 1mg/kg Q6h PRN \[max. 50mg\] for 5 days (B) Scheduled gabapentin 3 mg/kg \[max 150 mg\] Q6h for 5 days (C) PRN ibuprofen 10 mg/kg \[max. 500 mg\] Q6h PRN
- Tramadol/placebo/ibuprofen (Type: PLACEBO_COMPARATOR): (A) Scheduled tramadol 1mg/kg Q6h \[max. 50mg\] for 5 days; plus tramadol 1mg/kg Q6h PRN \[max. 50mg\] for 5 days (B) Scheduled placebo of same volume Q6h for 5 days (C) PRN ibuprofen 10 mg/kg \[max. 500 mg\] Q6h PRN

Based on this trial design, predict the completion outcome and termination type (if applicable).